Publications
Detailed Information
Resected Colorectal Liver Metastases: Does the Survival Differ According to Postoperative Chemotherapy Regimen?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sun Young | - |
dc.contributor.author | Kim, Hee Jun | - |
dc.contributor.author | Hong, Yong Sang | - |
dc.contributor.author | Jung, Kyung Hae | - |
dc.contributor.author | Choi, Hyo Seong | - |
dc.contributor.author | Park, Sang-Jae | - |
dc.contributor.author | Nam, Byung-Ho | - |
dc.contributor.author | Kim, Dae Yong | - |
dc.contributor.author | Chang, Hee Jin | - |
dc.contributor.author | Kim, Seong Hoon | - |
dc.contributor.author | Oh, Jae Hwan | - |
dc.contributor.author | Park, Ji Won | - |
dc.date.accessioned | 2012-05-22T07:58:04Z | - |
dc.date.available | 2012-05-22T07:58:04Z | - |
dc.date.issued | 2009-12-15 | - |
dc.identifier.citation | JOURNAL OF SURGICAL ONCOLOGY; Vol.100 8; 713-718 | ko_KR |
dc.identifier.issn | 0022-4790 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76253 | - |
dc.description.abstract | Background and Objectives: We compared clinical outcomes in patients who were treated with different chemotherapeutic regimens after resection of hepatic metastases from colorectal cancer (CRC). Methods: Between August 2001 and June 2008, 156 patients who entered into chemotherapy of adjuvant intent after hepatic metastasectomy were reviewed retrospectively. Results: Of the 156 patients, 58 patients were treated with oxaliplatin/fluoropyrimidines (group I), 48 with irinotecan/fluoropyrimidines (group II), and 50 with fluoropyrimidines alone (group III). In the univariate analysis, there was a marginally significant difference among the three groups with respect to the disease-free survival (DFS): 23.4 months in group I, 14.1 months in group II, and 16.3 months in group III, P = 0.088). Group I showed better DFS when compared to the other two groups combined (group II and III) (P = 0.03). Multivariable analysis showed a marginally significant gain in the DFS for group I (P = 0.068). Multiple metastases (P = 0.045) and positive resection margin (P = 0.003) were significantly associated with poorer DFS. Conclusion: Postoperative combination chemotherapy of oxaliplatin/fluoropyrimidines seemed to show better DFS when compared to fluoropyrimidine monotherapy or irinotecan-based combination in patients who underwent liver metastasectomy. J. Surg. Oncol. 2009;100:713-718. (C) 2009 Wiley-Liss, Inc. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | WILEY-LISS | ko_KR |
dc.subject | colorectal neoplasms | ko_KR |
dc.subject | liver | ko_KR |
dc.subject | neoplasm metastasis | ko_KR |
dc.subject | chemotherapy | ko_KR |
dc.title | Resected Colorectal Liver Metastases: Does the Survival Differ According to Postoperative Chemotherapy Regimen? | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김선영 | - |
dc.contributor.AlternativeAuthor | 김희준 | - |
dc.contributor.AlternativeAuthor | 홍용상 | - |
dc.contributor.AlternativeAuthor | 정경해 | - |
dc.contributor.AlternativeAuthor | 박지원 | - |
dc.contributor.AlternativeAuthor | 최효성 | - |
dc.contributor.AlternativeAuthor | 오재환 | - |
dc.contributor.AlternativeAuthor | 박상재 | - |
dc.contributor.AlternativeAuthor | 김성훈 | - |
dc.contributor.AlternativeAuthor | 남병호 | - |
dc.contributor.AlternativeAuthor | 장희진 | - |
dc.contributor.AlternativeAuthor | 김대용 | - |
dc.identifier.doi | 10.1002/jso.21403 | - |
dc.citation.journaltitle | JOURNAL OF SURGICAL ONCOLOGY | - |
dc.description.citedreference | Mitry E, 2008, J CLIN ONCOL, V26, P4906, DOI 10.1200/JCO.2008.17.3781 | - |
dc.description.citedreference | Taylor I, 2008, EUR J CANCER, V44, P1198, DOI 10.1016/j.ejca.2008.04.007 | - |
dc.description.citedreference | Nordlinger B, 2008, LANCET, V371, P1007 | - |
dc.description.citedreference | YCHOU M, 2008, J CLIN ONCOLOGY, V26 | - |
dc.description.citedreference | Saltz LB, 2007, J CLIN ONCOL, V25, P3456, DOI 10.1200/JCO.2007.11.2144 | - |
dc.description.citedreference | Dy GK, 2007, J CLIN ONCOL, V25, P3469, DOI 10.1200/JCO.2007.10.7128 | - |
dc.description.citedreference | DEGRAMONT A, 2007, J CLIN ONCOL, V25, P4007 | - |
dc.description.citedreference | Portier G, 2006, J CLIN ONCOL, V24, P4976, DOI 10.1200/JCO.2006.06.8353 | - |
dc.description.citedreference | Colucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113 | - |
dc.description.citedreference | VANCUTSEM E, 2005, ASCO ANN M P | - |
dc.description.citedreference | Andre T, 2004, NEW ENGL J MED, V350, P2343 | - |
dc.description.citedreference | Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71 | - |
dc.description.citedreference | Dale PS, 2004, ANN SURG, V239, P825 | - |
dc.description.citedreference | TOUMIGAND C, 2004, J CLIN ONCOL, V22, P229 | - |
dc.description.citedreference | SHIN HR, 2004, CANC RES TREAT, V36, P103 | - |
dc.description.citedreference | Choti MA, 2002, ANN SURG, V235, P759 | - |
dc.description.citedreference | LANGER B, 2002, ASCO ANN M P | - |
dc.description.citedreference | de Gramont A, 2000, J CLIN ONCOL, V18, P2938 | - |
dc.description.citedreference | Douillard JY, 2000, LANCET, V355, P1041 | - |
dc.description.citedreference | Fong Y, 1999, ANN SURG, V230, P309 | - |
dc.description.citedreference | FONG Y, 1999, ANN SURG, V230, P318 | - |
dc.description.citedreference | Fong YM, 1997, J CLIN ONCOL, V15, P938 | - |
dc.description.citedreference | Millikan KW, 1997, SURG CLIN N AM, V77, P27 | - |
dc.description.citedreference | MOERTEL CG, 1995, ANN INTERN MED, V122, P321 | - |
dc.description.citedreference | SCHEELE J, 1990, BRIT J SURG, V77, P1241 | - |
dc.description.citedreference | SCHLAG P, 1990, EUR J SURG ONCOL, V16, P360 | - |
dc.description.citedreference | WAGNER JS, 1984, ANN SURG, V199, P502 | - |
dc.description.tc | 2 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.